{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=20", "query": { "condition": "HER2-normal", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1187, "total_pages": 119, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:22:22.605Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Hematologic Neoplasms", "Ovarian Cancer", "HER2-positive Advanced Solid Tumors", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Cervical Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "tebotelimab 1 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 3 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 10 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 30 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 120 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 300 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 400 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 600 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 800 mg", "type": "BIOLOGICAL" }, { "name": "tebotelimab 1200 mg", "type": "BIOLOGICAL" }, { "name": "margetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2017-08-18", "completion_date": "2023-02-08", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219268" }, { "nct_id": "NCT02115048", "title": "Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Translational Research in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 44, "start_date": "2014-07", "completion_date": "2018-11", "has_results": true, "last_update_posted_date": "2019-12-26", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Northridge, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "San Luis Obispo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115048" }, { "nct_id": "NCT05837455", "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cancer of the Breast" ], "interventions": [ { "name": "VENTANA MIB-1 Ki67 assay", "type": "DEVICE" }, { "name": "Oncotype DX® Recurrence Score", "type": "DEVICE" }, { "name": "PAM50-based Prosigna breast cancer gene signature assay", "type": "DEVICE" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Combination anthracycline and/or taxane based treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2024-05-30", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05837455" }, { "nct_id": "NCT05159778", "title": "Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Imprime PGG", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-11-09", "completion_date": "2023-04-12", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 16, "location_summary": "Tucson, Arizona • Denver, Colorado • Miami, Florida + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05159778" }, { "nct_id": "NCT04016935", "title": "EndoPredict® Extended Endocrine Trial (EXET)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Invasive Breast Cancer" ], "interventions": [ { "name": "Observational", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Myriad Genetic Laboratories, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 855, "start_date": "2019-07-02", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 52, "location_summary": "Burbank, California • Roseville, California • Fort Myers, Florida + 40 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04016935" }, { "nct_id": "NCT05161195", "title": "Roll-over Study to Allow Continued Access to Ribociclib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 134, "start_date": "2022-07-07", "completion_date": "2030-08-14", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 16, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161195" }, { "nct_id": "NCT03584009", "title": "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 103, "start_date": "2018-09-06", "completion_date": "2021-05-06", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03584009" }, { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-03-14", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" }, { "nct_id": "NCT00634088", "title": "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg", "type": "DRUG" }, { "name": "Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg", "type": "DRUG" }, { "name": "Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg", "type": "DRUG" }, { "name": "Ixabepilone + Lapatinib + Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634088" }, { "nct_id": "NCT00558103", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 163, "start_date": "2007-12", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-11-12T17:22:22.605Z", "location_count": 17, "location_summary": "Long Beach, California • Sacramento, California • Denver, Colorado + 14 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00558103" } ] }